These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2381138)

  • 1. Gemfibrozil absorption and elimination in kidney and liver disease.
    Knauf H; Kölle EU; Mutschler E
    Klin Wochenschr; 1990 Jul; 68(13):692-8. PubMed ID: 2381138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanism of action of xipamide and its classification as a "low ceiling diuretic". Pharmacodynamic-pharmacokinetic studies in healthy volunteers and in kidney and liver patients].
    Knauf H; Mutschler E
    Arzneimittelforschung; 2005; 55(1):1-14. PubMed ID: 15727159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
    Kyrklund C; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2003 Jun; 73(6):538-44. PubMed ID: 12811363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of prazosin.
    Jaillon P
    Clin Pharmacokinet; 1980; 5(4):365-76. PubMed ID: 6994981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency.
    Krakamp B; Tanswell P; Leidig P; Vogel H; Schmitz R; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):71-3. PubMed ID: 2917592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
    Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
    Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apparent reduced absorption of gemfibrozil when given with colestipol.
    Forland SC; Feng Y; Cutler RE
    J Clin Pharmacol; 1990 Jan; 30(1):29-32. PubMed ID: 2303577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
    Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of nitrendipine in patients with chronic liver diseases.
    Zilly W; Rämsch KD; Gothe M
    J Cardiovasc Pharmacol; 1988; 12 Suppl 4():S175-7. PubMed ID: 2468869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bioavailability study with two gemfibrozil tablet formulations in healthy volunteers.
    Borges NC; Mendes GD; Barrientos-Astigarraga RE; Zappi E; Mendes FD; De Nucci G
    Arzneimittelforschung; 2005; 55(7):382-6. PubMed ID: 16080277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of renal function on the pharmacokinetics of gemfibrozil.
    Evans JR; Forland SC; Cutler RE
    J Clin Pharmacol; 1987 Dec; 27(12):994-1000. PubMed ID: 3481387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
    Niemi M; Tornio A; Pasanen MK; Fredrikson H; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Jun; 62(6):463-72. PubMed ID: 16758263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofibrate disposition in renal failure and acute and chronic liver disease.
    Gugler R; Kürten JW; Jensen CJ; Klehr U; Hartlapp J
    Eur J Clin Pharmacol; 1979 Jun; 15(5):341-7. PubMed ID: 456406
    [No Abstract]   [Full Text] [Related]  

  • 15. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paracetamol disposition and metabolite kinetics in patients with chronic renal failure.
    Prescott LF; Speirs GC; Critchley JA; Temple RM; Winney RJ
    Eur J Clin Pharmacol; 1989; 36(3):291-7. PubMed ID: 2744070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley rats and Syrian golden hamsters.
    Dix KJ; Coleman DP; Jeffcoat AR
    Drug Metab Dispos; 1999 Jan; 27(1):138-46. PubMed ID: 9884323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tryptophan loading test as a function parameter in liver diseases].
    Rössle M; Herz R; Hiss W; Gerok W
    Klin Wochenschr; 1983 Mar; 61(6):277-83. PubMed ID: 6865262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
    Säwe J
    Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.